Why the study?
Hyperglycemia-mediated cardiomyocyte damage is associated with inflammation and AMPK inactivation, prompting exploration of the protective effects of liraglutide on the AMPK pathway and GLP-1 receptor in diabetic cardiomyopathy.
Does liraglutide reduce hyperglycemia-induced cardiomyocyte death in an in vitro model?
Population
Cardiomyocytes exposed to high-glucose stress
Comparison
Liraglutide vs high-glucose stress alone
Design
In vitro experimental study
Authors
Loading...
Liraglutide may protect high-glucose cardiomyocytes via AMPK/GLP-1R; leaves open clinical translation in diabetic cardiomyopathy.
Does liraglutide reduce hyperglycemia-induced cardiomyocyte death in an in vitro model?
Liraglutide protects cardiomyocytes from hyperglycemia-induced damage by activating the AMPK pathway and upregulating the GLP-1 receptor.
Ma et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: